Pfizer spends billions to develop new drugs. It’s not satisfied. So it’s launching a startup
Pharma giant Pfizer is launching a six-person spinoff to develop new drugs in a bid to capture the scrappy intensity of biotech startups.
There’s a popular theory about the limitations of global pharma companies: For all their skyscrapers and strategy reviews and private jets, they’re simply too knotted up in bureaucracy to realize how many great drugs are gathering dust in their vaults.
Now, the biggest of Big Pharma is out do do something about that. Pfizer, home to nearly 100,000 employees, on Monday announced the launch of a six-person startup to develop new drugs.
This may seem odd
